Methylisothiazolinone Contact Allergy Prevalence in Western Canada: Increased Detection With 2000 ppm Patch Test Allergen

Background: Contact allergy to methylisothiazolinone (MI) or to the combination of methylchloroisothiazolinone and MI (MCI/MI) is an important and increasing cause of allergic contact dermatitis, with prevalence rates higher than 10% in some centers. Objectives: The objective of this retrospective c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cutaneous medicine and surgery 2017-05, Vol.21 (3), p.207-210
Hauptverfasser: Wilford, Jessica E., de Gannes, Gillian C.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 210
container_issue 3
container_start_page 207
container_title Journal of cutaneous medicine and surgery
container_volume 21
creator Wilford, Jessica E.
de Gannes, Gillian C.
description Background: Contact allergy to methylisothiazolinone (MI) or to the combination of methylchloroisothiazolinone and MI (MCI/MI) is an important and increasing cause of allergic contact dermatitis, with prevalence rates higher than 10% in some centers. Objectives: The objective of this retrospective chart review is to provide a western Canadian perspective on whether the positive patch testing rate to MCI/MI or MI increased during the testing period of 2008 to 2015 and whether the addition of MI at 2000 ppm resulted in increased detection. Methods: We conducted a retrospective chart review of patients who tested positive (n = 104) of 2177 total patients who were patch tested for MCI/MI or MI at a community dermatology clinic in Vancouver, British Columbia, Canada, from January 2008 through April 2015. Results: One hundred and four patients had positive patch testing results for MCI/MI, MI, or both. Positive results increased over the study period, with the highest prevalence in 2015 at 9.41% for MCI/MI, 12.94% for MI, and 15.29% for either. When testing for MI at 2000 ppm was introduced in 2013, the initial positive patch testing prevalence was 6.6%, followed by 10.1% in 2014, and 12.9% in 2015. Conclusions: We demonstrate an increasing prevalence of MCI/MI and MI allergy between 2008 and 2015, with the highest prevalence of 15.29% in 2015 for MCI/MI and/or MI allergy. The addition of MI 2000 ppm greatly increased the positive patch testing yield for MI. Our results support the importance of continued efforts to monitor and regulate these preservatives.
doi_str_mv 10.1177/1203475417690307
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1878181386</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1203475417690307</sage_id><sourcerecordid>1878181386</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-bd2e0e23310c7ab16a73bbda53305e87b4bc2cc5a294a99e3cea9970313bc2f63</originalsourceid><addsrcrecordid>eNp1kc1rGzEQxUVpqFMn956KoJdcttGstKvd3oLzCQnxwSHHZVY7jtesJVeSC-5fHxm7DQSCDiN4v_dm4DH2DcRPAK3PIRdS6UKBLmshhf7EjqGEItMg6s_pn-Rsp4_Y1xCWQgiAQn1ho7ySQiiljtn2geJiO_TBxUWPf93QW2eJT5yNaCK_GAbyL1s-9fQHB7KGeG_5M4VI3vIJWuzwF7-zxhMG6vglRTKxd4np44LnaSVfr1d8itEs-Cz5DpFkT9jRHIdAp4c5Zk_XV7PJbXb_eHM3ubjPjCyLmLVdToJyKUEYjS2UqGXbdlhIKQqqdKtakxtTYF4rrGuShtLQQoJMwryUY3a2z11793uTLmhWfTA0DGjJbUIDla6gAlnt0B_v0KXbeJuua3IotKrk7o2Z2FPGuxA8zZu171fotw2IZldL876WZPl-CN60K-r-G_71kIBsDwR8obetHwa-ApEklCQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2157483838</pqid></control><display><type>article</type><title>Methylisothiazolinone Contact Allergy Prevalence in Western Canada: Increased Detection With 2000 ppm Patch Test Allergen</title><source>SAGE Complete A-Z List</source><source>MEDLINE</source><creator>Wilford, Jessica E. ; de Gannes, Gillian C.</creator><creatorcontrib>Wilford, Jessica E. ; de Gannes, Gillian C.</creatorcontrib><description>Background: Contact allergy to methylisothiazolinone (MI) or to the combination of methylchloroisothiazolinone and MI (MCI/MI) is an important and increasing cause of allergic contact dermatitis, with prevalence rates higher than 10% in some centers. Objectives: The objective of this retrospective chart review is to provide a western Canadian perspective on whether the positive patch testing rate to MCI/MI or MI increased during the testing period of 2008 to 2015 and whether the addition of MI at 2000 ppm resulted in increased detection. Methods: We conducted a retrospective chart review of patients who tested positive (n = 104) of 2177 total patients who were patch tested for MCI/MI or MI at a community dermatology clinic in Vancouver, British Columbia, Canada, from January 2008 through April 2015. Results: One hundred and four patients had positive patch testing results for MCI/MI, MI, or both. Positive results increased over the study period, with the highest prevalence in 2015 at 9.41% for MCI/MI, 12.94% for MI, and 15.29% for either. When testing for MI at 2000 ppm was introduced in 2013, the initial positive patch testing prevalence was 6.6%, followed by 10.1% in 2014, and 12.9% in 2015. Conclusions: We demonstrate an increasing prevalence of MCI/MI and MI allergy between 2008 and 2015, with the highest prevalence of 15.29% in 2015 for MCI/MI and/or MI allergy. The addition of MI 2000 ppm greatly increased the positive patch testing yield for MI. Our results support the importance of continued efforts to monitor and regulate these preservatives.</description><identifier>ISSN: 1203-4754</identifier><identifier>EISSN: 1615-7109</identifier><identifier>DOI: 10.1177/1203475417690307</identifier><identifier>PMID: 28300444</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Allergies ; British Columbia - epidemiology ; Dermatitis ; Dermatitis, Allergic Contact - diagnosis ; Dermatitis, Allergic Contact - epidemiology ; Dermatology ; Female ; Humans ; Male ; Middle Aged ; Patch Tests - methods ; Preservatives, Pharmaceutical - adverse effects ; Retrospective Studies ; Sensitivity and Specificity ; Thiazoles - adverse effects ; Transdermal medication</subject><ispartof>Journal of cutaneous medicine and surgery, 2017-05, Vol.21 (3), p.207-210</ispartof><rights>The Author(s) 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-bd2e0e23310c7ab16a73bbda53305e87b4bc2cc5a294a99e3cea9970313bc2f63</citedby><cites>FETCH-LOGICAL-c365t-bd2e0e23310c7ab16a73bbda53305e87b4bc2cc5a294a99e3cea9970313bc2f63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1203475417690307$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1203475417690307$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21800,27903,27904,43600,43601</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28300444$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wilford, Jessica E.</creatorcontrib><creatorcontrib>de Gannes, Gillian C.</creatorcontrib><title>Methylisothiazolinone Contact Allergy Prevalence in Western Canada: Increased Detection With 2000 ppm Patch Test Allergen</title><title>Journal of cutaneous medicine and surgery</title><addtitle>J Cutan Med Surg</addtitle><description>Background: Contact allergy to methylisothiazolinone (MI) or to the combination of methylchloroisothiazolinone and MI (MCI/MI) is an important and increasing cause of allergic contact dermatitis, with prevalence rates higher than 10% in some centers. Objectives: The objective of this retrospective chart review is to provide a western Canadian perspective on whether the positive patch testing rate to MCI/MI or MI increased during the testing period of 2008 to 2015 and whether the addition of MI at 2000 ppm resulted in increased detection. Methods: We conducted a retrospective chart review of patients who tested positive (n = 104) of 2177 total patients who were patch tested for MCI/MI or MI at a community dermatology clinic in Vancouver, British Columbia, Canada, from January 2008 through April 2015. Results: One hundred and four patients had positive patch testing results for MCI/MI, MI, or both. Positive results increased over the study period, with the highest prevalence in 2015 at 9.41% for MCI/MI, 12.94% for MI, and 15.29% for either. When testing for MI at 2000 ppm was introduced in 2013, the initial positive patch testing prevalence was 6.6%, followed by 10.1% in 2014, and 12.9% in 2015. Conclusions: We demonstrate an increasing prevalence of MCI/MI and MI allergy between 2008 and 2015, with the highest prevalence of 15.29% in 2015 for MCI/MI and/or MI allergy. The addition of MI 2000 ppm greatly increased the positive patch testing yield for MI. Our results support the importance of continued efforts to monitor and regulate these preservatives.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Allergies</subject><subject>British Columbia - epidemiology</subject><subject>Dermatitis</subject><subject>Dermatitis, Allergic Contact - diagnosis</subject><subject>Dermatitis, Allergic Contact - epidemiology</subject><subject>Dermatology</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Patch Tests - methods</subject><subject>Preservatives, Pharmaceutical - adverse effects</subject><subject>Retrospective Studies</subject><subject>Sensitivity and Specificity</subject><subject>Thiazoles - adverse effects</subject><subject>Transdermal medication</subject><issn>1203-4754</issn><issn>1615-7109</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc1rGzEQxUVpqFMn956KoJdcttGstKvd3oLzCQnxwSHHZVY7jtesJVeSC-5fHxm7DQSCDiN4v_dm4DH2DcRPAK3PIRdS6UKBLmshhf7EjqGEItMg6s_pn-Rsp4_Y1xCWQgiAQn1ho7ySQiiljtn2geJiO_TBxUWPf93QW2eJT5yNaCK_GAbyL1s-9fQHB7KGeG_5M4VI3vIJWuzwF7-zxhMG6vglRTKxd4np44LnaSVfr1d8itEs-Cz5DpFkT9jRHIdAp4c5Zk_XV7PJbXb_eHM3ubjPjCyLmLVdToJyKUEYjS2UqGXbdlhIKQqqdKtakxtTYF4rrGuShtLQQoJMwryUY3a2z11793uTLmhWfTA0DGjJbUIDla6gAlnt0B_v0KXbeJuua3IotKrk7o2Z2FPGuxA8zZu171fotw2IZldL876WZPl-CN60K-r-G_71kIBsDwR8obetHwa-ApEklCQ</recordid><startdate>201705</startdate><enddate>201705</enddate><creator>Wilford, Jessica E.</creator><creator>de Gannes, Gillian C.</creator><general>SAGE Publications</general><general>SAGE PUBLICATIONS, INC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201705</creationdate><title>Methylisothiazolinone Contact Allergy Prevalence in Western Canada: Increased Detection With 2000 ppm Patch Test Allergen</title><author>Wilford, Jessica E. ; de Gannes, Gillian C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-bd2e0e23310c7ab16a73bbda53305e87b4bc2cc5a294a99e3cea9970313bc2f63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Allergies</topic><topic>British Columbia - epidemiology</topic><topic>Dermatitis</topic><topic>Dermatitis, Allergic Contact - diagnosis</topic><topic>Dermatitis, Allergic Contact - epidemiology</topic><topic>Dermatology</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Patch Tests - methods</topic><topic>Preservatives, Pharmaceutical - adverse effects</topic><topic>Retrospective Studies</topic><topic>Sensitivity and Specificity</topic><topic>Thiazoles - adverse effects</topic><topic>Transdermal medication</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wilford, Jessica E.</creatorcontrib><creatorcontrib>de Gannes, Gillian C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cutaneous medicine and surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wilford, Jessica E.</au><au>de Gannes, Gillian C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Methylisothiazolinone Contact Allergy Prevalence in Western Canada: Increased Detection With 2000 ppm Patch Test Allergen</atitle><jtitle>Journal of cutaneous medicine and surgery</jtitle><addtitle>J Cutan Med Surg</addtitle><date>2017-05</date><risdate>2017</risdate><volume>21</volume><issue>3</issue><spage>207</spage><epage>210</epage><pages>207-210</pages><issn>1203-4754</issn><eissn>1615-7109</eissn><abstract>Background: Contact allergy to methylisothiazolinone (MI) or to the combination of methylchloroisothiazolinone and MI (MCI/MI) is an important and increasing cause of allergic contact dermatitis, with prevalence rates higher than 10% in some centers. Objectives: The objective of this retrospective chart review is to provide a western Canadian perspective on whether the positive patch testing rate to MCI/MI or MI increased during the testing period of 2008 to 2015 and whether the addition of MI at 2000 ppm resulted in increased detection. Methods: We conducted a retrospective chart review of patients who tested positive (n = 104) of 2177 total patients who were patch tested for MCI/MI or MI at a community dermatology clinic in Vancouver, British Columbia, Canada, from January 2008 through April 2015. Results: One hundred and four patients had positive patch testing results for MCI/MI, MI, or both. Positive results increased over the study period, with the highest prevalence in 2015 at 9.41% for MCI/MI, 12.94% for MI, and 15.29% for either. When testing for MI at 2000 ppm was introduced in 2013, the initial positive patch testing prevalence was 6.6%, followed by 10.1% in 2014, and 12.9% in 2015. Conclusions: We demonstrate an increasing prevalence of MCI/MI and MI allergy between 2008 and 2015, with the highest prevalence of 15.29% in 2015 for MCI/MI and/or MI allergy. The addition of MI 2000 ppm greatly increased the positive patch testing yield for MI. Our results support the importance of continued efforts to monitor and regulate these preservatives.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>28300444</pmid><doi>10.1177/1203475417690307</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1203-4754
ispartof Journal of cutaneous medicine and surgery, 2017-05, Vol.21 (3), p.207-210
issn 1203-4754
1615-7109
language eng
recordid cdi_proquest_miscellaneous_1878181386
source SAGE Complete A-Z List; MEDLINE
subjects Adult
Aged
Aged, 80 and over
Allergies
British Columbia - epidemiology
Dermatitis
Dermatitis, Allergic Contact - diagnosis
Dermatitis, Allergic Contact - epidemiology
Dermatology
Female
Humans
Male
Middle Aged
Patch Tests - methods
Preservatives, Pharmaceutical - adverse effects
Retrospective Studies
Sensitivity and Specificity
Thiazoles - adverse effects
Transdermal medication
title Methylisothiazolinone Contact Allergy Prevalence in Western Canada: Increased Detection With 2000 ppm Patch Test Allergen
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T04%3A28%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Methylisothiazolinone%20Contact%20Allergy%20Prevalence%20in%20Western%20Canada:%20Increased%20Detection%20With%202000%20ppm%20Patch%20Test%20Allergen&rft.jtitle=Journal%20of%20cutaneous%20medicine%20and%20surgery&rft.au=Wilford,%20Jessica%20E.&rft.date=2017-05&rft.volume=21&rft.issue=3&rft.spage=207&rft.epage=210&rft.pages=207-210&rft.issn=1203-4754&rft.eissn=1615-7109&rft_id=info:doi/10.1177/1203475417690307&rft_dat=%3Cproquest_cross%3E1878181386%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2157483838&rft_id=info:pmid/28300444&rft_sage_id=10.1177_1203475417690307&rfr_iscdi=true